Twenty years on: the impact of fragments on drug discovery

 

Erlanson D, Fesik S, Hubbard R, Jahnke W, Jhoti H,

Nature Reviews Drug Discovery
2016 vol: 15 (9) pp: 605-619

Abstract

After 20 years of sometimes quiet growth, fragment-based drug discovery (FBDD) has become mainstream. More than 30 drug candidates derived from fragments have entered the clinic, with two approved and several more in advanced trials. FBDD has been widely applied in both academia and industry, as evidenced by the large number of papers from universities, non-profit research institutions, biotechnology companies and pharmaceutical companies. Moreover, FBDD draws on a diverse range of disciplines, from biochemistry and biophysics to computational and medicinal chemistry. As the promise of FBDD strategies becomes increasingly realized, now is an opportune time to draw lessons and point the way to the future. This Review briefly discusses how to design fragment libraries, how to select screening techniques and how to make the most of information gleaned from them. It also shows how concepts from FBDD have permeated and enhanced drug discovery efforts.

View Publication

Topics: Measure binding affinity, Monolith, Microscale Thermophoresis, Publications, Reviews, Screening

 

 

Previous Article
Two functionally distinct kinetochore pools of BubR1 ensure accurate chromosome segregation
Two functionally distinct kinetochore pools of BubR1 ensure accurate chromosome segregation

Next Article
Structure of a cytoplasmic 11-subunit RNA exosome complex
Structure of a cytoplasmic 11-subunit RNA exosome complex